sivopixant

Sivopixant is a highly selective small molecule antagonist of the purinergic P2X3 receptor. It was developed to treat refractory or unexplained chronic cough and is also being investigated for neuropathic pain and sleep apnea syndrome. Unlike earlier P2X3 antagonists such as gefapixant, sivopixant demonstrates high selectivity for the P2X3 receptor over the P2X2/3 receptor subtype, resulting in a lower incidence of taste disturbance—a common side effect with less selective agents. Sivopixant has shown efficacy in reducing cough frequency and improving quality of life in clinical trials. The drug was originally developed by Shionogi[1][3][6].

Other names

(E/Z)-Sivopixant2414285-40-6S0N1VEG94IS-0N1VEG94IS 0N1VEG94IUNII-S0N1VEG94IUNII-S-0N1VEG94IUNII-S 0N1VEG94I1640808-39-4(2S)-3-[3-[(4-chlorophenyl)methyl]-2,6-dioxo-4-(4-pyridin-2-yloxyanilino)-1,3,5-triazin-1-yl]-2-methylpropanoic acid